Number of participants achieving 'response' by IGA · scalp psoriasis
Steroid leads to higher number of participants achieving 'response' by IGA compared with vitamin D (high certainty).
1 finding from 1 review
Quality of life · scalp psoriasis
1 finding from 1 review
Number of participants withdrawing due to adverse events (AE) · scalp psoriasis
Steroid probably leads to lower number of participants withdrawing due to adverse events (AE) compared with vitamin D (moderate certainty).
1 finding from 1 review
Number of participants achieving 'response' by PGA · scalp psoriasis
Steroid probably leads to higher number of participants achieving 'response' by PGA compared with vitamin D (moderate certainty).
1 finding from 1 review
Number of participants achieving 'clearance' by IGA · scalp psoriasis
Steroid plus vitamin D probably leads to higher number of participants achieving 'clearance' by IGA compared with steroid (moderate certainty).
1 finding from 1 review
Number of participants achieving 'response' by IGA · scalp psoriasis
Steroid plus vitamin D probably leads to higher number of participants achieving 'response' by IGA compared with steroid (moderate certainty).
1 finding from 1 review
Quality of life · scalp psoriasis
1 finding from 1 review
Number of participants withdrawing due to adverse events (AE) · scalp psoriasis
Steroid plus vitamin D showed no clear difference in number of participants withdrawing due to adverse events (AE) compared with steroid (moderate certainty).
1 finding from 1 review
Mycological cure · patients with tinea cruris and tinea corporis
1 finding from 1 review
Recurrence · patients with tinea cruris and tinea corporis
Naftifine 1% cream once or twice daily showed no clear difference in relapse or recurrence Evidence of clinical or mycological infection… compared with placebo cream once or twice daily (low certainty).
1 finding from 1 review
Participant‐judged cure Not assessed · patients with tinea cruris and tinea corporis
1 finding from 1 review
Duration of treatment until clinical cure Not assessed · patients with tinea cruris and tinea corporis
1 finding from 1 review
Mycological cure · patients with tinea cruris and tinea corporis
1 finding from 1 review
Clinical cure · patients with tinea cruris and tinea corporis
1 finding from 1 review
Adverse effects Reported by investigators 'and' or 'or' participants · patients with tinea cruris and tinea corporis
It is very uncertain whether azoles changes adverse effects Reported by investigators 'and' or 'or' participants compared with allylamines (very low certainty).
1 finding from 1 review
Relapse or recurrence Evidence of clinical and mycological relapse after the end of treatment. Assessed in 3 studies · patients with tinea cruris and tinea corporis
It is very uncertain whether azoles changes relapse or recurrence Evidence of clinical and mycological relapse… compared with allylamines (very low certainty).
1 finding from 1 review
Participant‐judged cure Not assessed · patients with tinea cruris and tinea corporis
1 finding from 1 review
Duration of treatment until clinical cure Not assessed · patients with tinea cruris and tinea corporis
1 finding from 1 review
no estimate extracted
1 study · 7 participants
Very low
Mycological cure · patients with tinea cruris and tinea corporis
Azoles showed no clear difference in mycological cure Negative KOH microscopy and culture. Treatment… compared with moderate‐potent corticosteroid/azole combinations (low certainty).
1 finding from 1 review
Clinical cure · patients with tinea cruris and tinea corporis
Terbinafine 1% cream/gel may leads to higher clinical cure Resolution of clinical signs and symptoms. Treatment… compared with placebo cream/gel (low certainty).
1 finding from 1 review